Skip to main content

Coronavirus: Vaccination

Question for Department of Health and Social Care

UIN HL2857, tabled on 4 October 2021

To ask Her Majesty's Government whether the type of vaccine to be used for the third COVID-19 vaccination for patients who are immunosuppressed will (1) be decided by the doctors treating the patient, or (2) be decided by those administering doses at clinics.

Answered on

15 October 2021

For those aged 18 years old and over, the Joint Committee on Vaccination and Immunisation (JCVI) advise a preference for mRNA vaccines for the third primary dose, with the option of the AstraZeneca Vaxzevria vaccine for individuals who have received this vaccine previously.. The dosage is a third full dose of the relevant COVID-19 vaccine. The specialist involved should advise on whether the patient fulfils the eligibility criteria and on the timing of any third primary dose. NHS England and NHS Improvement issued Updated JCVI guidance for vaccinating immunosuppressed individuals with a third primary dose on 2 September 2021, on the vaccine preference for patients who are immunosuppressed and the guidance for how to proceed with third primary doses. A copy of the guidance is attached.

In exceptional circumstances, persons who received a mRNA COVID-19 vaccine previously may be offered a third primary dose of the AstraZeneca Vaxzevria vaccine following a decision by a health professional on an individualised basis. For those aged 12 to 17 years old, the Pfizer vaccine remains the preferred choice.